Allergy Diagnostics Market to Rise at a 11.1% CAGR from 2021 to 2026
The Allergy
Diagnostics Market is projected to reach USD 8.2 billion by 2026 from
USD 4.8 billion in 2021, at a CAGR of 11.1% from 2021 to 2026. Factors such as,
rising environmental pollution levels, high incidence of allergic diseases,
increasing funds by organizations in allergy diagnostics are anticipated to
drive growth of the allergy diagnostics market.
Get Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=232871701
Key Market Players:
Thermo Fisher Scientific Inc., (US), Siemens Healthineers
(Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA
(France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische
Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation
(US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US),
Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR
Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON
Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH
(Germany), and Erba Group (UK).
Market Dynamics
DRIVER: Rising environmental pollution levels
Exposure to indoor and outdoor air pollutants, allergens,
and occupational exposure are the major risk factors causing chronic
respiratory diseases. The prevalence of allergic disorders among the urban
population is higher than those living in rural areas due to the higher
exposure to environmental pollutants in cities (as a result of vehicular
pollution and industrial activities).
As per the WHO, more than 80% of people living in urban
areas are exposed to air quality levels that exceed the WHO safety limits;
though this is a global trend, its effects are more severe in the urban areas
of low-income countries. This is a major indicator for the growth of the
allergy diagnostics market, as air pollution from motor vehicles has been
indicated as one of the major risk factors responsible for allergic diseases.
Epidemiological and toxicological research reveals a causal
relationship between air pollution and the increased incidence of asthma,
allergic rhinitis, and other allergic disorders. Studies have also demonstrated
a significant increase in the incidence and exacerbation of asthma in urban
locations with elevated PM 2.5 (particulate matter of size 2.5 micrometers or
less), nitrogen dioxide, and ozone concentrations.
OPPORTUNITY: Use of mHealth in allergy diagnosis
The use of mHealth for the diagnosis of rhinitis is
currently limited, with a small number of mHealth tools for allergic rhinitis
(AR) diagnosis published in peer-reviewed journals. Recent developments in
integrated biosensors, wireless communication, and power harvesting techniques
generate a new breed of point-of-care devices. However, AR is a very common
disease. Any diagnostic device connected to a smartphone (e.g., peak nasal
inspiratory flow meters or intranasal biosensors) would need to be inexpensive
to be affordable.
The monitoring of the control of allergic multimorbidity
(rhinitis, conjunctivitis, and asthma) has been approached by several apps.
Allergymonitor, for example, helps in monitoring the symptoms and medication
intake, which is then matched to local pollen concentrations. Similarly, the
MASK (Mobile Airways Sentinel Network) MASK-Air, initially called Allergy
Diary, uses a visual analog scale (VAS) for eye, nose, & asthma symptoms,
work impairment, and a global assessment. The data collected by the users of
this app have led to new insights on work productivity, treatment patterns, and
phenotypes of allergic diseases.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701
TREND: Reagent rental agreements
Reagent rental agreements are sales agreements between end
users (such as hospitals and diagnostic laboratories) and allergy diagnostic
product manufacturers. Under these agreements, the end user rents or purchases
instruments at a subsidized rate by entering into a reagent-purchase contract
with the manufacturer. This mutually beneficial agreement lowers the initial
capital investment for the end user while assuring the manufacturer of
purchases over a substantial time period. In some cases, analyzers are rented
out to the end user at a cost-per-test rate.
Reagent rental agreements and cost-per-test contracts
provide significant benefits to laboratories focusing on reducing costs. They
also help laboratories avoid major fixed capital expenditures associated with
the purchase of new equipment. For high-volume laboratories, these expenditures
are substantially higher than those of a standard laboratory. Moreover, with
the average contract lasting between 5 and 10 years, this allows laboratories
to remain updated with the latest innovations in allergy diagnostics. Some
contracts also include service/maintenance expenses in the total cost,
providing additional savings for laboratories.
Key Developments:
·
In 2021, Hitachi Chemical Diagnostics, Inc. has
been renamed Minaris Medical America, Inc. By uniting the medical business
group companies under the name of Minaris Medical, Hitachi aims to strengthen
its global presence and expand business operations in the field of in-vitro
diagnostics. The companies are a part of Showa Denko Materials Co., Ltd.
(renamed from Hitachi Chemical Co., Ltd. on Oct 1, 2020).
·
In 2021, PerkinElmer Inc. entered into an
agreement with Immunodiagnostic Systems Holdings PLC to acquire the later. The
acquisition will enable PerkinElmer Inc. to strengthen its position in the
ImmunoDiagnostics (IDS) market. IDS would be incorporated under EUROIMMUN
Medizinische LABORDIAGNOSTIKA AG, a company offering allergy products and
solutions.
·
In 2020, NEOGEN Corporation launched Reveal 3-D
for Gluten
·
In 2019, Romer Labs Division Holding GmbH opened
its APAC Solutions Centre in Singapore. The APAC Solutions Centre features new
facilities for food allergen testing.
·
In 2018, Omega Diagnostics Group PLC and
Immunodiagnostic Systems (IDS) entered into a supply agreement through which
Immunodiagnostic Systems (IDS) is the official distributor of allergy tests
offered by Omega Diagnostics Group PLC.
Buy Now: https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=232871701
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on
30,000 high growth niche opportunities/threats which will impact 70% to 80% of
worldwide companies' revenues. Currently servicing 7500 customers worldwide
including 80% of global Fortune 1000 companies as clients. Almost 75,000 top
officers across eight industries worldwide approach MarketsandMarkets™ for
their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are
tracking global high growth markets following the "Growth Engagement Model
- GEM". The GEM aims at proactive collaboration with the clients to
identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors.
MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies, innovators, strategic players)
annually in high growth emerging segments. MarketsandMarkets™ is determined to
benefit more than 10,000 companies this year for their revenue planning and
help them take their innovations/disruptions early to the market by providing
them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and
market research platform, "Knowledgestore" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights
along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Related Reports:
Veterinary Vaccines Market: https://www.marketsandmarkets.com/Market-Reports/animal-veterinary-vaccines-market-1233.html
Veterinary Diagnostics Market: https://www.marketsandmarkets.com/Market-Reports/veterinary-diagnostics-market-26017452.html
Vaccines Market: https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html
Immunoassay Market: https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html
In vitro Diagnostics Market: https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html
Comments
Post a Comment